Leukemias, lymphomas, and other hematologic cancers:

Indications for INQOVI:

Myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS with the French-American-British subtypes and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.


Not substitutable for an IV decitabine product within a cycle. May premedicate with antiemetics. Swallow whole. Take on empty stomach. 1 tab once daily on Days 1 through 5 of each 28-day cycle. Give for a minimum of 4 cycles until disease progression or unacceptable toxicity. Dose modifications for adverse reactions: see full labeling.


Not established.


Risk of myelosuppression, infectious complications. Obtain CBCs at baseline, prior to each cycle, and as needed to monitor response and toxicity (see full labeling). Delay the next cycle if ANC <1000/microliter and platelets <50000/microliter in absence of active disease. Renal impairment (moderate): monitor; for severe or ESRD: not studied. Embryo-fetal toxicity. Advise to use effective contraception during and for 6 months (females of reproductive potential) or 3 months (males w. female partners) after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for ≥2 weeks after the last dose).

Pharmacologic Class:

Nucleoside analogue + cytidine deaminase inhibitor.


Avoid concomitant drugs metabolized by cytidine deaminase.

Adverse Reactions:

Fatigue, constipation, hemorrhage, myalgia, mucositis, arthralgia, nausea, dyspnea, diarrhea, rash, dizziness, febrile neutropenia, edema, headache, cough, decreased appetite, upper respiratory tract infection, pneumonia, and transaminase increased, lab abnormalities (decreased leukocytes, platelet count, neutrophil count, and hemoglobin); febrile neutropenia, pneumonia, sepsis.

Generic Availability:


How Supplied:

Tabs—5 (blister card)

Pricing for INQOVI

5 tablets of 35mg/100mg carton (Qty: 1)
Appx. price $7655